Evidence mapPaperPMID 3327654Full record

Trial reportControlled clinical trials1987

The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.

D H Blankenhorn, R L Johnson, S A Nessim, S P Azen, M E Sanmarco, R H Selzer

Registry-linked trialAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Controlled clinical trials, 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000599. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000599 phase3completed

Cholesterol-Lowering Atherosclerosis Study (CLAS)

Ran1980Registered outcomes0Posted comparisons0ConditionsArterial Occlusive Diseases, Atherosclerosis, Cardiovascular Diseases, Carotid Artery DiseasesArmscolestipol, diet, fat-restricted, niacin
Open the trial in the graph
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Lipid-lowering for peripheral arterial disease of the lower limb.The Cochrane database of systematic reviews · 2007
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. NADFrontiers in physiology · 2020
    Review
  9. Niacin: an old lipid drug in a new NADJournal of lipid research · 2019
    Article
  10. Review
  11. Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.The International journal of angiology : official publication of the International College of Angiology, Inc · 2017
    Review
  12. Article
  13. Carotid intima media thickness in type 2 diabetes mellitus with ischemic stroke.Indian journal of endocrinology and metabolism · 2013
    Article
  14. Problems and possible solutions for therapy with statins.The International journal of angiology : official publication of the International College of Angiology, Inc · 2013
    Review
  15. Article
  16. Atherosclerosis: current status of prevention and treatment.The International journal of angiology : official publication of the International College of Angiology, Inc · 2011
    Article
  17. Article
  18. Article
  19. Carotid vascular abnormalities in primary hyperparathyroidism.The Journal of clinical endocrinology and metabolism · 2009
    Article
  20. Thiazolidinediones and cardiovascular disease.Current atherosclerosis reports · 2005
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

D H Blankenhorn
R L Johnson
S A Nessim
S P Azen
M E Sanmarco
R H Selzer
Jet Propulsion Laboratory · USOklahoma Medical Research Foundation · USUniversity of Southern California · US

Funding

NHLBI NIH HHS R01-HL-23619
6 · The paper itself

Abstract

The Cholesterol Lowering Atherosclerosis Study (CLAS) is a prospective, placebo-controlled, angiographic trial designed to test the hypothesis that aggressive lowering of LDL cholesterol with concomitant increase in HDL cholesterol will reverse or retard the atherosclerotic process. Specifically, CLAS was designed to determine whether combined therapy with colestipol plus niacin will produce clinically significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions. To this purpose, 188 subjects were randomized to diet plus drug or diet plus placebo. We report on methodological aspects of planning and evaluating this study, including the choice of the study population, procedures for recruitment, the experimental design including sample size considerations, methods for evaluating outcome, and methods for evaluating compliance to treatment. Comparison of baseline data indicated no significant differences between groups at the time of randomization. Subjects were predominantly male, Caucasian, 54 years of age, 20% above ideal weight, with normal blood pressure. The average age at bypass was 50 years. The average lipids were cholesterol (243 mg/dL), HDL (45 mg/dL), and LDL (168 mg/dL). Finally, the distribution of baseline coronary stenosis was equivalent between the two groups (average number of lesions per subject = 10.6).

Indexed as

AdultAngiographyArteriosclerosisCaliforniaCholesterol, DietaryCholesterol, LDLClinical Trials as TopicColestipolDietary FatsHumansMaleMiddle AgedNiacinProspective StudiesRandom AllocationResearch DesignCholesterol, DietaryCholesterol, LDLColestipolDietary FatsNiacin

Identifiers

PMID3327654
OpenAlexW2069737615

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.